Optimizing AAV Safety Summit Hilton Boston Logan Airport, Boston

With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be.

In this context, the 2nd Annual Optimizing AAV Safety Summit is returning in 2023, bringing together genetic therapy leaders across non-clinical development, clinical development, toxicology, biodistribution, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day.

By addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic, analyzing potential integration risks of AAV serotypes, and investigating regulatory approaches to safety packages for submission, this meeting will inform how to streamline AAV safety processes to de-risk delays and shorten timelines to approval.

Join us in Boston to be part of the solution to bringing safer, effective genetic therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.

Speakers: Eric David, Chief Executive Officer of Gene Therapy, BridgeBio, Johny Yao Director, Pharmacology, Translational Research, Voyager, Nicolas Wein, Principal Investigator, The Research Institute at Nationwide Children’s Hospital, Christian Vetterman, Senior Scientist and Associate Director, BioMarin, Alison Shottek, Senior Project Manager, Preclinical Programs, Modalis Therapeutics, Sandra Raff, Senior Director – Drug Safety and Pharmacovigilance, Ultragenyx Pharmaceuticals, Albena Patroneva, Senior Vice President Clinical Development, Neurogene, Kathrin Meyer, Principle Investigator, The Research Institute at Nationwide Children’s Hospital, Anas Fathallah, Co-Founder, Lapix Therapeutics, Darin Falk, Chief Scientific Officer, Lacerta, Genevieve Laforet, Vice President – Clinical Development, Aspa Therapeutics, Effie Albanis, Senior Vice President Early Clinical and Translational Research, Neurogene, Mohammadsharif Tabebordbar, Co-Founder and Chief Scientific Officer, Kate Therapeutics, Abraham Scaria, Chief Scientific Officer, AGTC, Kali Stasi, Senior Vice President Clinical Development, Adverum, Mansuo Shannon, Chief Scientific Officer, Selecta Biosciences, Eva Andres-Mateos, Senior Director, Translational Research, Atsena Therapeutics, Weidong Xiao, Professor, Indiana University, Ronald Crystal, Professor and Chairman, Department of Genetic Medicine, Weill Cornell Medical College, Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc.